US Patent

US8580304 — Pharmaceutical composition

Formulation · Assigned to GlaxoSmithKline LLC · Expires 2032-01-28 · 6y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects novel pharmaceutical compositions containing a specific solvate of trametinib dimethyl sulfoxide.

USPTO Abstract

Disclosed are novel pharmaceutical compositions containing N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, methods of using the compositions in therapy and processes for preparing the same.

Drugs covered by this patent

trametinib-dimethyl-sulfoxide (TRAMETINIB DIMETHYL SULFOXIDE)

Patent Metadata

Patent number: US8580304
Jurisdiction: US
Classification: Formulation
Expires: 2032-01-28
Drug substance claim: No
Drug product claim: Yes
Assignee: GlaxoSmithKline LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.